Disc Medicine, Inc. (IRON) stock
IRONNasdaqPharmaceutical PreparationsFiscal year ends December 31
$77.98+1.41 (+1.84%)
Close on Nov 18, 2026Market cap $2.99BP/E –Yield –
Disc Medicine operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Disc Medicine's operating income for the twelve months ending Jun 30, 2026 was -$269.27M. For fiscal 2025 it was -$236.02M. The highest annual figure on record is -$30.93M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$236.02M | – |
| FY2024 | Dec 31, 2024 | -$129.72M | – |
| FY2023 | Dec 31, 2023 | -$91.13M | – |
| FY2022 | Dec 31, 2022 | -$47.48M | – |
| FY2021 | Dec 31, 2021 | -$30.93M | – |
| FY2020 | Dec 31, 2020 | -$34.04M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$65.08M | – |
| Q1 FY2026 | Mar 31, 2026 | -$69.52M | – |
| Q4 FY2025 | Dec 31, 2025 | -$66.97M | – |
| Q3 FY2025 | Sep 30, 2025 | -$67.70M | – |
| Q2 FY2025 | Jun 30, 2025 | -$61.41M | – |
| Q1 FY2025 | Mar 31, 2025 | -$39.95M | – |
| Q4 FY2024 | Dec 31, 2024 | -$34.55M | – |
| Q3 FY2024 | Sep 30, 2024 | -$32.86M | – |
| Q2 FY2024 | Jun 30, 2024 | -$30.85M | – |
| Q1 FY2024 | Mar 31, 2024 | -$31.46M | – |
| Q4 FY2023 | Dec 31, 2023 | -$29.71M | – |
| Q3 FY2023 | Sep 30, 2023 | -$18.96M | – |
| Q2 FY2023 | Jun 30, 2023 | -$17.33M | – |
| Q1 FY2023 | Mar 31, 2023 | -$25.13M | – |
| Q4 FY2022 | Dec 31, 2022 | -$15.02M | -173.9% |
| Q3 FY2022 | Sep 30, 2022 | -$10.48M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.02M | – |
| Q1 FY2022 | Mar 31, 2022 | -$9.96M | – |
| Q4 FY2021 | Dec 31, 2021 | $20.33M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.45M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.32M | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.49M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.79M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.95M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.67M | – |
| Q1 FY2020 | Mar 31, 2020 | -$9.63M | – |
See a number that looks wrong?